team organized the First Joint Meeting on Lung Cancer last September 2018, in
Nice, at the Palais Sarde.
2 days of conferences, discussions between researcher from MD Anderson and OncoAge.
The goal of this collaboration is to make new promising discoveries for lung cancer patients.
At the meeting, high quality speakers from the MD Anderson and the FHU OncoAge, exchanged on the latest new treatments biomarkers and discoveries on lung cancer.
This year we have chosen to dedicate this meeting to lung cancer, but also some thoracic pre-neoplastic diseases, such as Chronic Obstructive Pulmonary Disease (COPD). Within this context, a partnership with research teams, scientists and physicians between the FHU OncoAge and the MD Anderson Cancer Center has been initiated.
13 speakers : (G.Calin, V. Papadimitrakopoulou, J. Wang, S.Mani, S. Hanash, J. Heymach, I. Wistuba, D. Hong, P. Hofman, M. Ilie, J.Y. Blay, L. Yvan-Charvet, P. Saintigny)
15 partners and sponsors (La Ligne contre le Cancer, Canceropôle, Roche, Abbvie, BMS, Astra Zeneca, Qiagen, UCA, MSD, CIUS, Métropole Nice, CHU Nice)
This partnership aims at working within the context of age-related lung cancer and non-tumor lung diseases as both age-related chronic diseases and cancer share genomic, immune, metabolic and other biological abnormalities.
In the future, there will be each year if possible, a Joint Meeting on Lung Cancer in Houston or in Nice.
OncoAge is a Hospital-University
Federation (FHU) dedicated to foster innovation for ageing population and
Cancer management. It has been awarded in December 2015 by AVIESAN and it is
supported by the Hospital University of Nice (CHU) and the Côte d’Azur
OncoAge brings together the CHU of
Nice, the Center Antoine Lacassagne (CAL), the Lenval Foundation, members of
AVIESAN of the Côte d’Azur University, Léon Bérard Center (CLB) of Lyon,
Gustave Roussy Institute of Villejuif, teams of research institutes IRCAN,
IPMC, iBV, C3M, L2PM, Inria, the Department of Mathematics of the UCA. Through
these teams the FHU involves INSERM, CNRS, Inria, CEA and UCA.
These structures bring together
their respective strengths in order to develop projects devoted to the
development of care, research, innovation and education/training in the field
of cancer and ageing.
The University of Texas MD Anderson
Cancer Center (MDACC) is one of the world’s most respected centers devoted
exclusively to cancer patient care, research, education and prevention.
The mission of The University of
Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation,
and the world through outstanding programs that integrate patient care, research
and prevention, and through education for undergraduate and graduate students, trainees,
professionals, employees and the public.
It shall be the premier cancer
center in the world, based on the excellence of its people, their research-driven
patient care and its science.
Nicolas Glaichenhaus de l’Institut de Pharmacologie Moléculaire et Cellulaire (UNS, CNRS) vient de recevoir le prix Marcel Dassault pour financer son projet de recherche sur les patients atteints de schizophrénie. Il espère ainsi pouvoir développer un algorithme de prédiction permettant au psychiatre d’identifier d’emblée, sur la base d’une simple prise de sang, le traitement qui aura le plus de chance d’être efficace pour son patient.